Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Natera (NTRA)
NASDAQ:NTRA
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.38Last Year’s EPS
-0.65Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: 27.75%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted Natera's strong financial and operational performance, with record revenue growth, increased oncology test volumes, and significant clinical data achievements. While there were some challenges related to weather impacts and litigation expenses, the overall outlook remains positive with raised guidance and strong cash flow generation.Company Guidance
During the Q3 2024 earnings call for Natera (NTRA), the company provided updated guidance, projecting annual revenue expectations to be between $1.61 billion and $1.64 billion, representing a 50% year-over-year growth, marking the fastest full-year growth since becoming a public company. The company achieved a record quarterly revenue of $439.8 million, up 64% from the previous year, with gross margins reaching a record 62%. Signatera clinical units experienced significant growth, reaching 137,000 tests in the quarter, a 54% increase year-over-year. Cash generation was notable, as Natera generated $34.5 million in cash, contributing to the updated guidance of $50 million to $75 million in cash generation for the year. The company's strategic focus remains on maintaining cash flow positivity while continuing to invest in R&D and commercial expansion, particularly for its oncology segment.Record Revenue Growth
Natera achieved a record revenue of $439.8 million in Q3 2024, representing a 64% increase year-over-year. This marks the highest quarterly revenue growth in the company's history.
Oncology Test Volume Increase
Performed approximately 137,000 oncology tests in Q3, a 54% increase from the previous year, marking significant growth in the oncology segment.
Strong Financial Performance
Generated $34.5 million in cash and reported a gross margin of 62%, both records for the company. Raised guidance for the year with revenue expectations now at $1.61 billion to $1.64 billion, implying a 50% revenue growth for the full year.
Significant Clinical Data Publication
Published groundbreaking Galaxy data in Nature Medicine, showing strong support for MRD testing and adjuvant decision-making, a key milestone for clinical validation.
Improvement in Signatera ASP
Signatera ASP improved to approximately $1,050, indicating strong pricing performance and reimbursement success.
---
NTRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NTRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $135.12 | $160.97 | +19.13% |
| Aug 08, 2024 | $107.70 | $114.57 | +6.38% |
| May 09, 2024 | $95.55 | $105.29 | +10.19% |
| Feb 28, 2024 | $76.55 | $86.49 | +12.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Natera (NTRA) report earnings?
Natera (NTRA) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Natera (NTRA) earnings time?
Natera (NTRA) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NTRA EPS forecast?
NTRA EPS forecast for the fiscal quarter 2024 (Q4) is -0.38.
---